Genfit S.A.
Research Genfit S.A. (GNFT) on Bullrun: market cap EUR 531.02M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGNFT
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 531.02M
- Financial periodFY2025
- RevenueEUR 65.43M
- Revenue growth-2.3%
- Net income-EUR 85.97M
- Free cash flow-EUR 29.66M
- Gross margin99.5%
Valuation Snapshot
latest market cap is EUR 531.02M.
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD);
Frequently asked questions
What is Genfit S.A.'s market cap?
Genfit S.A.'s market capitalization is EUR 531.02M.
What does Genfit S.A. do?
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.